Media stories about PAVmed (NASDAQ:PAVM) have trended positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PAVmed earned a news sentiment score of 0.26 on Accern’s scale. Accern also gave news headlines about the company an impact score of 49.0241416392005 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of PAVmed (NASDAQ PAVM) opened at $4.44 on Tuesday. PAVmed has a fifty-two week low of $2.54 and a fifty-two week high of $10.34. The company has a quick ratio of 0.42, a current ratio of 0.42 and a debt-to-equity ratio of -0.26.

A number of brokerages recently issued reports on PAVM. Dawson James reiterated a “buy” rating and issued a $10.10 price objective on shares of PAVmed in a report on Tuesday, September 5th. ValuEngine cut shares of PAVmed from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th.

COPYRIGHT VIOLATION NOTICE: “PAVmed (PAVM) Earning Positive News Coverage, Analysis Shows” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.

Insider Buying and Selling by Quarter for PAVmed (NASDAQ:PAVM)

Receive News & Stock Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related stocks with our FREE daily email newsletter.